Scholars@Duke publication: Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: a 3-month phase 3 trial (trial #1)

Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: a 3-month phase 3 trial (trial #1)

Publication , Conference

Connor, K; Budd, K; Snavely, D; Liu, K; Hutzel-Mann, J; Benca, R; Krystal, A; Roth, T; Michelson, D; Herring, WJ

Published in: JOURNAL OF SLEEP RESEARCH

September 2012

JOURNAL OF SLEEP RESEARCH

0962-1105

September 2012

97 / 97

APA

Chicago

ICMJE

MLA

NLM

Connor, K., Budd, K., Snavely, D., Liu, K., Hutzel-Mann, J., Benca, R., … Herring, W. J. (2012). Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: a 3-month phase 3 trial (trial #1). In JOURNAL OF SLEEP RESEARCH (Vol. 21, pp. 97–97).

Connor, K., K. Budd, D. Snavely, K. Liu, J. Hutzel-Mann, R. Benca, A. Krystal, T. Roth, D. Michelson, and W. J. Herring. “Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: a 3-month phase 3 trial (trial #1).” In JOURNAL OF SLEEP RESEARCH, 21:97–97, 2012.

Connor K, Budd K, Snavely D, Liu K, Hutzel-Mann J, Benca R, Krystal A, Roth T, Michelson D, Herring WJ. Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: a 3-month phase 3 trial (trial #1). JOURNAL OF SLEEP RESEARCH. 2012. p. 97–97.

JOURNAL OF SLEEP RESEARCH

0962-1105

September 2012

97 / 97